The Economic Stimulus and Science

A fixed percentage of a country's GDP should be committed to research.

Written byAlastair J.J. Wood
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

In early February, the House voted to approve the $787 billion economic recovery package and this was signed into law by President Obama. The bill contains something for everyone including scientists—$10 billion for National Institutes of Health (NIH), $1.3 billion for the National Center for Research Resources (NCRR), including $1 billion for construction and renovation of extramural research facilities, $700 million for the Agency for Healthcare Research and Quality (AHRQ) and $2.5 billion for the National Science Foundation (NSF).

Were it not that the purpose of the bill was to attempt a rescue of our teetering economy, this would indeed be a time to celebrate. The additional funds to the scientific enterprise is sorely needed and long overdue but it is hard not to have some misgivings at the manifest "short termism" of the overall scientific funding process. For example, language included in the bill instructs the NIH director that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies